NCT05224583
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
Enrolling by Invitation
Not specifiedAges 18+ObservationalMethodist Health SystemInvestigator-initiated
~50 participants
Updated 2026-03-20 on ClinicalTrials.gov
What's tested:Simultaneous Liver-Kidney Transplant
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To characterize the prevalence of BKV in the SLK patient population at (Methodist Dallas Medical Center)MDMC.
Measured over over a 6-year period (2015 to 2020).
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Lori Kautzman, MD · PRINCIPAL_INVESTIGATOR · Methodist Health System
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 18 years or older
SLK recipients transplanted at MDMC between 2015-2020
Exclusion
Below 18 years of age
Patients who did not undergo SLK transplant at MDMC
What this trial measures
- To characterize the prevalence of BKV in the SLK patient population at (Methodist Dallas Medical Center)MDMC.over a 6-year period (2015 to 2020).
number of SLK transplant recipients who were transplanted at (Methodist Dallas Medical Center)MDMC